Lypohypertrophy in patients receiving insulin therapy: state of the art
As known insulin therapy is associated with induration of subcutaneous fat at injections sites called lypohypertrophy. It develops at any age and at anysite regardless of duration of the treatment. The size of lypohypertrophy varies in a wide range. Numerous studies have been conducted to elucidatem...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2011-06-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/5642 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327349013676032 |
|---|---|
| author | Natalya Ivanovna Volkova Il'ya Yur'evich Davidenko |
| author_facet | Natalya Ivanovna Volkova Il'ya Yur'evich Davidenko |
| author_sort | Natalya Ivanovna Volkova |
| collection | DOAJ |
| description | As known insulin therapy is associated with induration of subcutaneous fat at injections sites called lypohypertrophy. It develops at any age and at anysite regardless of duration of the treatment. The size of lypohypertrophy varies in a wide range. Numerous studies have been conducted to elucidatemechanisms of lypohypertrophy (LH) and its risk factors including young age, low or high body mass index, frequency of the change of needles andinjection sites, female gender, and type 1 diabetes mellitus. It was shown that insulin crystals induce a local immune reaction and thereby interfere withadipocyte differentiation. At the same time, patients with LH have elevated titters of anti-insulin antibodies. The problem with LH is uncontrollableabsorption of insulin from injection sites. We noticed that patients with a target glucose level due to insulin therapy undergo its apparently causelessperiodic rises. Comparative ultrasonic examination of subcutaneous fat at different injection sites and control body areas revealed specific pathologicalchanges in adipose issue. This finding provided a basis for the hypothesis that LH can be detected by ultrasonography of subcutaneous fat. It wasconfirmed by the results of examination of 50 patients with DM1 treated with insulin of whom 41 were found to have pathological changes at injectionsites. |
| format | Article |
| id | doaj-art-9549e1ced11c4328a2c381ff837b92b1 |
| institution | Kabale University |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2011-06-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-9549e1ced11c4328a2c381ff837b92b12025-08-20T03:47:54ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782011-06-01142868910.14341/2072-0351-56425600Lypohypertrophy in patients receiving insulin therapy: state of the artNatalya Ivanovna Volkova0Il'ya Yur'evich Davidenko1Rostov State Medical University, Rostov-on-DonRostov State Medical University, Rostov-on-DonAs known insulin therapy is associated with induration of subcutaneous fat at injections sites called lypohypertrophy. It develops at any age and at anysite regardless of duration of the treatment. The size of lypohypertrophy varies in a wide range. Numerous studies have been conducted to elucidatemechanisms of lypohypertrophy (LH) and its risk factors including young age, low or high body mass index, frequency of the change of needles andinjection sites, female gender, and type 1 diabetes mellitus. It was shown that insulin crystals induce a local immune reaction and thereby interfere withadipocyte differentiation. At the same time, patients with LH have elevated titters of anti-insulin antibodies. The problem with LH is uncontrollableabsorption of insulin from injection sites. We noticed that patients with a target glucose level due to insulin therapy undergo its apparently causelessperiodic rises. Comparative ultrasonic examination of subcutaneous fat at different injection sites and control body areas revealed specific pathologicalchanges in adipose issue. This finding provided a basis for the hypothesis that LH can be detected by ultrasonography of subcutaneous fat. It wasconfirmed by the results of examination of 50 patients with DM1 treated with insulin of whom 41 were found to have pathological changes at injectionsites.https://www.dia-endojournals.ru/jour/article/view/5642lypohypertrophyinsulin therapydiabetes mellitusultrasonographyinsulin |
| spellingShingle | Natalya Ivanovna Volkova Il'ya Yur'evich Davidenko Lypohypertrophy in patients receiving insulin therapy: state of the art Сахарный диабет lypohypertrophy insulin therapy diabetes mellitus ultrasonography insulin |
| title | Lypohypertrophy in patients receiving insulin therapy: state of the art |
| title_full | Lypohypertrophy in patients receiving insulin therapy: state of the art |
| title_fullStr | Lypohypertrophy in patients receiving insulin therapy: state of the art |
| title_full_unstemmed | Lypohypertrophy in patients receiving insulin therapy: state of the art |
| title_short | Lypohypertrophy in patients receiving insulin therapy: state of the art |
| title_sort | lypohypertrophy in patients receiving insulin therapy state of the art |
| topic | lypohypertrophy insulin therapy diabetes mellitus ultrasonography insulin |
| url | https://www.dia-endojournals.ru/jour/article/view/5642 |
| work_keys_str_mv | AT natalyaivanovnavolkova lypohypertrophyinpatientsreceivinginsulintherapystateoftheart AT ilyayurevichdavidenko lypohypertrophyinpatientsreceivinginsulintherapystateoftheart |